Canadian Investors: 3 Top Undervalued Stocks to Buy Now
The Motley Fool
Published Jun 08, 2021 08:27
Updated Jun 08, 2021 08:45
Canadian Investors: 3 Top Undervalued Stocks to Buy Now
The Toronto Stock Exchange (TSX) outperforms Wall Street in the U.S. with its 14.89% year-to-date gain. In addition, Canada’s primary market benchmark closed above 20,000 for the first time on June 4, 2021. A Reuters poll results also expect the index to climb to 21,750 by year-end 2022. Frugal investors looking for great buys today can consider three top undervalued stocks.
Big lift from rising crude prices Rising oil prices are boosting energy stocks, including Vermilion Energy (TSX:VET)(NYSE:VET). Current investors are winning 83.98% thus far, in 2021. If you were to invest today, the share price is $10.45 at writing. The $1.66 billion oil and gas producer’s net income in Q1 2021 (quarter March 31, 2021) was $499.99 million versus the $1.31 billion net loss in Q1 2020.
Vermillion’s fund flows from operations (FFO) increased 20% to $162 million from the preceding quarter. Its two most dominant products, crude oil and natural gas, benefitted from higher prices during the quarter. Similarly, the company’s $83 million investment in exploration and development generated $79 million of free cash flow (FCF).
Management also notes the capital expenses helped Vermillion complete its winter drilling program in Canada and the majority of drilling plans for the year in Europe. The company capitalized on the 35% increase in global crude oil prices. Moreover, the bulk of FCF was used to reduce debt, resulting in a 5% decrease in net debt compared to year-end 2020.
Focus on high-need patients Viemed Healthcare (TSX:VMD)(NASDAQ:VMD), a $342.34 million provider of in-home durable medical equipment, flies under the radar. The Louisiana, U.S.-based company addresses illnesses such as chronic obstructive pulmonary disease (COPD), neuromuscular, and sleep apnea that the aging population commonly experience.
The healthcare stock trades at a bargain ($8.65 per share), although market analysts recommend a strong buy rating. They forecast a potential upside of between 72.7% ($14.84) and 107.3% ($17.93). In Q1 2021 (quarter ended March 31, 2021), core business revenues increased 12% to US$25.5 million versus Q1 2020.
While net income slid nearly 60%, the new patient uploads in March, the highest single month since the pandemic, is a welcome development. Viemed aims to be the independent leader when it comes to home therapy of patients with complex needs. It employs the highest number of respiratory therapists than any of its competitors in the country.
Spirits and cannabis Alcanna’s (TSX:CLIQ) trailing one-year price return is 109.6%. The current share price of $6.77 is a steal given the potential 103.1% upside to $13.75 based on analysts’ forecast. The $245.1 million company is the country’s premier retailer of wine, spirits, and beers. It dominates the markets in Alberta and British Columbia.
Get The App
Nova Cannabis, a publicly-listed company on the TSX Venture Exchange, is a majority-owned subsidiary. In Q1 2021 (quarter ended March 31, 2021), total sales increased by 2.8% versus Q1 2020. Alcanna’s same-store liquor sales grew by a significant 7.9%, while its liquor division gained 7.5% in gross margin dollars.
Alcanna expects Nova to be its growth catalyst. The subsidiary has 53 cannabis retail locations with 30 more stores in Alberta and Ontario under development or construction. Nova’s primary objective strategy is to be one of the largest and fastest-growing cannabis retailers that deliver compelling value to cannabis consumers.
Attractive to frugal investors Frugal investors should find the top three undervalued stocks attractive investment options. Given the growth drivers, each one promises superior gains.
The post Canadian Investors: 3 Top Undervalued Stocks to Buy Now appeared first on The Motley Fool Canada.
Fool contributor Christopher Liew has no position in any of the stocks mentioned.
This Article Was First Published on The Motley Fool
Written By: The Motley Fool
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.